Karyopharm Therapeutics Inc. (KPTI) Financial Statements (2024 and earlier)

Company Profile

Business Address 85 WELLS AVENUE
NEWTON, MA 02459
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments277,967228,615249,240261,956328,199146,469
Cash and cash equivalents135,188190,45985,918128,858118,02168,997
Short-term investments142,77938,156163,322133,098210,17877,472
Restricted cash and investments1,0646,3492,4811,117 200
Receivables47,08622,49712,8817,862  
Inventory, net of allowances, customer advances and progress billings4,2244,1062,644346  
Inventory4,2244,1062,644346  
Other undisclosed current assets19,82114,0399,2857,2896,4131,754
Total current assets:350,162275,606276,531278,570334,612148,423
Noncurrent Assets
Operating lease, right-of-use asset6,2387,9159,36310,617
Property, plant and equipment1,1391,6422,2193,0463,8632,185
Long-term investments and receivables   24,2152,0162,00129,396
Long-term investments   24,2152,0162,00129,396
Restricted cash and investments633637722714716290
Other undisclosed noncurrent assets 19,505    
Total noncurrent assets:8,01029,69936,51916,3936,58031,871
TOTAL ASSETS:358,172305,305313,050294,963341,192180,294
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities61,18870,72457,38041,86336,82527,110
Accounts payable2,7731,6034,4509854,3325,665
Accrued liabilities58,41569,12152,93040,87832,49321,445
Deferred revenue   2972,341
Debt    1,646  
Deferred rent credit     390
Other liabilities1,848678609500327133
Deferred revenue and credits22,224
Other undisclosed current liabilities2,8722,3161,917 9,362 
Total current liabilities:65,90873,71860,20346,35046,90449,467
Noncurrent Liabilities
Long-term debt and lease obligation170,105178,262129,213123,059102,664 
Long-term debt, excluding current maturities170,105169,293117,928109,857102,664 
Liabilities, other than long-term debt6,097  2,1923,9221,363
Deferred revenue and credits1,363
Deferred revenue    2,192
Deferred rent credit     3,922
Other liabilities      
Operating lease, liability6,0978,96911,28513,202
Other undisclosed noncurrent liabilities132,718124,02961,80373,5884,532 
Total noncurrent liabilities:308,920311,260202,301198,839111,1181,363
Total liabilities:374,828384,978262,504245,189158,02250,830
Equity
Equity, attributable to parent(16,656)(79,673)50,54649,774183,170129,464
Common stock1287765
Additional paid in capital1,327,9091,098,7761,119,632923,142857,156625,017
Accumulated other comprehensive income (loss)(638)191518(37)(244)(217)
Accumulated deficit(1,343,939)(1,178,648)(1,069,611)(873,338)(673,748)(495,341)
Total equity:(16,656)(79,673)50,54649,774183,170129,464
TOTAL LIABILITIES AND EQUITY:358,172305,305313,050294,963341,192180,294

Income Statement (P&L) ($ in thousands)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues157,074209,819108,08540,89330,3361,605
Revenue, net1,605
Cost of revenue
(Cost of Goods and Services Sold)
   (329)   
Gross profit:157,074209,819107,75640,89330,3361,605
Operating expenses(299,276)(308,090)(279,935)(230,168)(210,219)(132,143)
Other undisclosed operating income   329   
Operating loss:(142,202)(98,271)(171,850)(189,275)(179,883)(130,538)
Nonoperating income (expense)(22,720)(25,549)(24,114)(10,275)1,5021,617
Investment income, nonoperating2,3595822,8205,4224,0281,698
Interest and debt expense(24,996)(26,046)(27,140)(15,647)(2,493) 
Other undisclosed income from continuing operations before equity method investments, income taxes   27,14015,6472,493 
Loss from continuing operations before equity method investments, income taxes:(189,918)(149,866)(195,964)(199,550)(178,381)(128,921)
Other undisclosed income from continuing operations before income taxes24,99626,046    
Loss from continuing operations before income taxes:(164,922)(123,820)(195,964)(199,550)(178,381)(128,921)
Income tax expense(369)(268)(309)(40)(26)(63)
Loss from continuing operations:(165,291)(124,088)(196,273)(199,590)(178,407)(128,984)
Loss before gain (loss) on sale of properties:(124,088)(196,273)(199,590)(178,407)(128,984)
Net loss available to common stockholders, diluted:(165,291)(124,088)(196,273)(199,590)(178,407)(128,984)

Comprehensive Income ($ in thousands)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(165,291)(124,088)(196,273)(199,590)(178,407)(128,984)
Comprehensive loss:(165,291)(124,088)(196,273)(199,590)(178,407)(128,984)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(829)(327)555207(27)57
Comprehensive loss, net of tax, attributable to parent:(166,120)(124,415)(195,718)(199,383)(178,434)(128,927)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: